Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | STAT6 | P42226 | 1/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | APLNR | P35414 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.46 |
| ▸ | REN | P00797 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002373 | 0.94 | ACE (0.53) | F2STAT6C5AR1ACEAPLNR | |
| SCHEMBL5969903 | 0.93 | ACE (0.53) | F2STAT6C5AR1ACEAPLNR | |
| SCHEMBL8953791 | 0.92 | C5AR1 (0.52) | F2C5AR1ACEAPLNRREN | |
| SCHEMBL8953840 | 0.89 | C5AR1 (0.52) | F2C5AR1ACEAPLNRREN | |
| SCHEMBL2815390 | 0.89 | F2 (0.49) | F2STAT6C5AR1ACEAPLNR | |
| SCHEMBL8953877 | 0.87 | C5AR1 (0.55) | F2C5AR1APLNRREN | |
| SCHEMBL10622567 | 0.86 | C5AR1 (0.54) | F2C5AR1APLNRREN | |
| SCHEMBL9181890 | 0.84 | C5AR1 (0.50) | F2C5AR1APLNROPRM1OPRK1 | |
| SCHEMBL32691458 | 0.84 | SLC6A2 (0.61) | F2C5AR1OPRM1REN | |
| SCHEMBL30617831 | 0.83 | F2 (0.58) | F2C5AR1APLNROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | F2 1072/4885STAT6 2854/4885C5AR1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.